|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Radius
|
$57.5M
|
Second MPM Capital and The Wellcome Trust |
Radius is aiming to advance its lead bone anabolic therapy for osteoporosis into Phase II trials. |
|
Sangart
|
$50M
|
Leucadia National Corporation |
The money will be used to advance two large-scale Phase III clinical trials of Sangart's lead product candidate, Hemospan. |
|
Syndax
|
$40M
|
First Domain Associates and MPM Capital |
Syndax is developing cancer therapies. |
|
Aerovance
|
$32M
|
Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co. |
The money will be used to advance the asthma drug Aerovant into Phase IIb, scheduled to begin later this year |
|
Company NameNitec Pharma
|
$26M
|
NGN Capital Atlas Venture and Global Life Science Ventures |
Much of the money is budgeted to advance its therapy for rheumatoid arthritis. |
|
Amira
|
$25M
|
Novo |
Amira is developing new therapies for inflammatory diseases. |
|
Surface Logix
|
$20M
|
Fourth Venrock Associates, ARCH Venture Partners, CW Group, HBM BioVentures and Unilever Technology Ventures |
The developer has programs in cardiovascular, metabolic, inflammatory and fibrotic diseases. |
|
Egalet
|
$19.27M
|
Vaekstfonden Life Science Ventures |
Egalet has been using its technology for orally-released therapies to develop a pipeline of drugs for pain and cardiovascular uses. |
|
Axial Biotech
|
$15.3M
|
Johnson & Johnson Development Corporation |
The funds raised in this financing will be used to accelerate Axial Biotech's product development efforts and to prepare for the launch of its scoliosis genetic test late next year. |
|
Protemix
|
$14.5M
|
Novartis Venture Fund and NovaQuest |
Proceeds from the financing will be used to advance the clinical development of Protemix's lead product, PX811019 |